矿物甲基皮质类受体对手 在高血压中使用,以预防心力衰竭
1Division of Cardiology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
JACC. Heart failure
|May 8, 2025
概括
矿物质皮质类受体对抗剂 (MRAs) 在高血压患者的心力衰竭 (HF) 预防方面表现有前途. 早期的MRA治疗可以解决高血压的潜在机制,减少住院治疗和心血管死亡率.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 矿物质皮质类受体抗剂 (MRA) 是心力衰竭 (HF) 的确立治疗方法,减少死亡率和住院治疗.
- 在高血压患者中,MRAs在预防高血压的作用越来越被认可,但可能被低估.
研究的目的:
- 审查有关高血压中矿物质皮质类受体过激活的新兴证据.
- 通过针对这些未被充分认识到的机制,探索MRAs在预防HF方面的潜力.
主要方法:
- 关于矿物质皮质醇受体过度激活的最新研究和理论的文献综述.
- 分析了将高血压,矿物质皮质类受体通路和HF病原体联系在一起的证据.
主要成果:
- 高血压通常涉及未被认可的矿物质皮质醇受体过度激活,通过诸如初级阿尔多斯特隆主义和皮质醇失调等机制.
- 医疗药物治疗可以针对这些机制,这表明它在HF发育中起着预防作用.
结论:
- 在高血压管理中增加MRA的使用可能代表一种新的策略,以减少发生的高血压.
- 针对高血压早期的矿物质皮质激素受体过度激活,可以预防高血压的发展和进展.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316
Heart Failure Drugs: Diuretics
291
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
291
Heart Failure Drugs: β-Blockers
273
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
273
Antihypertensive Drugs: Angiotensin II Receptor Blockers
539
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
539
Antihypertensive Drugs: Direct Renin Inhibitors
443
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
443
Antihypertensive Drugs: Potassium-Sparing Diuretics
404
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
404


